Famitinib
As of the edition of 20 October 2026, Famitinib is a small molecule: stopped in 2025; acts on FLT1, FLT3 and FLT4 and 4 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 65, 10 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Digestive system; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product6 company-target rows are on route A because of Famitinib.
See the 6 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| PDGFRB | Platelet-derived growth factor receptor beta | P09619 |
| KIT | Mast/stem cell growth factor receptor Kit | P10721 |
| PDGFRA | Platelet-derived growth factor receptor alpha | P16234 |
| FLT1 | Vascular endothelial growth factor receptor 1 | P17948 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | P36888 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 10 | 8 | 0 | 1 |
| Phase 2 | 44 | 6 | 17 | 5 |
| Phase 3 | 10 | 1 | 4 | 4 |
| All trials | 65 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2009 to now |